Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    No substantive content changes were detected; the page continues to present the study overview, eligibility criteria, and planned outcomes for the Pembrolizumab + Olaparib trial. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T12:36:28.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    33 days ago
    Change Detected
    Summary
    Major update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.
    Difference
    3%
    Check dated 2025-10-05T17:32:09.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no substantive content changes detected.
    Difference
    0.1%
    Check dated 2025-09-28T10:39:52.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    The page now shows revision v3.0.2 (from v3.0.1); the 'Back to Top' element was removed.
    Difference
    0.2%
    Check dated 2025-09-14T00:29:27.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.
    Difference
    0.2%
    Check dated 2025-09-06T21:18:21.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as new content related to skin and connective tissue diseases and specific medications like pembrolizumab and olaparib. However, several previous topics and terms related to cancer and pharmacological classifications have been removed.
    Difference
    2%
    Check dated 2025-08-30T15:43:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.